Osimertinib inhibits the MYLK4-mediated phosphorylation of CDKAL1 to suppress stemness and chemoresistance in rhabdomyosarcoma.
Saved in:
| Title: | Osimertinib inhibits the MYLK4-mediated phosphorylation of CDKAL1 to suppress stemness and chemoresistance in rhabdomyosarcoma. |
|---|---|
| Authors: | Itano T; Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.; Department of Musculoskeletal Oncology, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan., Huang R; Department of Cellular Physiology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.; Department of Trauma Orthopedics, The Second Hospital of Dalian Medical University, Dalian, Liaoning, China., Ozaki T; Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan., Nakata E; Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan., Fujimura A; Department of Cellular Physiology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan. fujimura.atsushi@kagawa-u.ac.jp.; Department of Molecular Physiology, Kagawa University Faculty of Medicine, Kagawa, Japan. fujimura.atsushi@kagawa-u.ac.jp. |
| Source: | Signal transduction and targeted therapy [Signal Transduct Target Ther] 2026 Jan 22; Vol. 11 (1), pp. 26. Date of Electronic Publication: 2026 Jan 22. |
| Publication Type: | Letter |
| Journal Info: | Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101676423 Publication Model: Electronic Cited Medium: Internet ISSN: 2059-3635 (Electronic) Linking ISSN: 20593635 NLM ISO Abbreviation: Signal Transduct Target Ther Subsets: MEDLINE; In Process |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| FullText | Links: – Type: pdflink Text: Availability: 1 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 41565624 AccessLevel: 2 PubType: Editorial & Opinion PubTypeId: editorialOpinion PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Osimertinib inhibits the MYLK4-mediated phosphorylation of CDKAL1 to suppress stemness and chemoresistance in rhabdomyosarcoma. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Itano+T%22">Itano T</searchLink>; Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.; Department of Musculoskeletal Oncology, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.<br /><searchLink fieldCode="AU" term="%22Huang+R%22">Huang R</searchLink>; Department of Cellular Physiology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.; Department of Trauma Orthopedics, The Second Hospital of Dalian Medical University, Dalian, Liaoning, China.<br /><searchLink fieldCode="AU" term="%22Ozaki+T%22">Ozaki T</searchLink>; Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.<br /><searchLink fieldCode="AU" term="%22Nakata+E%22">Nakata E</searchLink>; Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.<br /><searchLink fieldCode="AU" term="%22Fujimura+A%22">Fujimura A</searchLink>; Department of Cellular Physiology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan. fujimura.atsushi@kagawa-u.ac.jp.; Department of Molecular Physiology, Kagawa University Faculty of Medicine, Kagawa, Japan. fujimura.atsushi@kagawa-u.ac.jp. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101676423%22">Signal transduction and targeted therapy</searchLink> [Signal Transduct Target Ther] 2026 Jan 22; Vol. 11 (1), pp. 26. <i>Date of Electronic Publication: </i>2026 Jan 22. – Name: TypePub Label: Publication Type Group: TypPub Data: Letter – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Nature+Publishing+Group%22">Nature Publishing Group </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101676423 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2059-3635 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2220593635%22">20593635 </searchLink><i>NLM ISO Abbreviation: </i>Signal Transduct Target Ther <i>Subsets: </i>MEDLINE; In Process |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41565624 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1038/s41392-025-02548-6 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 26 Titles: – TitleFull: Osimertinib inhibits the MYLK4-mediated phosphorylation of CDKAL1 to suppress stemness and chemoresistance in rhabdomyosarcoma. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Itano T – PersonEntity: Name: NameFull: Huang R – PersonEntity: Name: NameFull: Ozaki T – PersonEntity: Name: NameFull: Nakata E – PersonEntity: Name: NameFull: Fujimura A IsPartOfRelationships: – BibEntity: Dates: – D: 22 M: 01 Text: 2026 Jan 22 Type: published Y: 2026 Identifiers: – Type: issn-electronic Value: 2059-3635 Numbering: – Type: volume Value: 11 – Type: issue Value: 1 Titles: – TitleFull: Signal transduction and targeted therapy Type: main |
| ResultId | 1 |
